Import From China Increased By More Than 21%, Focus To Reduce Dependence: NITI Aayog Vice Chairman Suman Bery

New Delhi : As India’s import to China has increased by more than 21%, the apex public policy think tank of the Government of India, opined that New Delhi should not only focus on reducing overall trade with Beijing but it should be on reducing New Delhi’s dependence on Beijing for certain critical inputs.

Speaking to the news agency PTI, National Institution for Transforming India (NITI) Aayog vice chairman Suman Bery underscored that the right response is to diversify to other sources of supply for critical inputs including active pharmaceutical ingredients (APIs) and supply chain for renewables.

Notably, China is the world’s largest producer and exporter of APIs and many Indian companies depend on imports of the ingredients to produce various formulations. The critical statement from the top official came as China’s exports to India climbed to $118.5 billion, a year-on-year increase of 21.7%, whereas China’s imports from India dwindled to $17.48 billion, a year-on-year decline of 37.9% in 2022.

“India’s focus should not be on the trade deficit with China. It should be on our dependence on China for certain critical inputs,” he told the news agency. He was asked what measures India should take to reduce its rising trade deficit with China.

According to recent data released by Chinese customs, the trade between India and China touched an all-time high of USD 135.98 billion in 2022, while New Delhi’s trade deficit with Beijing crossed the USD 100 billion mark for the first time despite frosty bilateral relations. To reduce the trade deficit with China, Bery suggested that India should formulate a sector-by-sector strategy. He said Chinese enterprises are looking for markets and they want to hold on to the Indian market. “And to do that, they should be prevented from being monopolists, by the way,” Bery emphasised.

  • Related Posts

    Zydus Lifesciences Q4FY26 net profit rises 9%

    Zydus board approved a buyback of up to Rs 1100 crore at Rs 1,150 per share, along with a 100 percent dividend for FY26. Zydus Lifesciences reported a rise in…

    Chemists strike on May 20: Reasons behind today’s all-India strike

    While major pharmacy chains and government medical outlets will remain operational, the strike highlights significant tensions within the industry that could impact access to medications nationwide. The All India Organisation…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Zydus Lifesciences Q4FY26 net profit rises 9%

    Zydus Lifesciences Q4FY26 net profit rises 9%

    Chemists strike on May 20: Reasons behind today’s all-India strike

    Chemists strike on May 20: Reasons behind today’s all-India strike

    AbbVie loses patent plea for Hep C drug

    AbbVie loses patent plea for Hep C drug

    GSK’s Calpol a well-known trademark: High Court

    GSK’s Calpol a well-known trademark: High Court

    3 arrested for allegedly posing as doctors using forged MBBS degrees

    3 arrested for allegedly posing as doctors using forged MBBS degrees

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures